A synthetic analog of growth-hormone-releasing hormone designed to last longer in the body.
CJC-1295 is a modified version of the first 29 amino acids of growth-hormone-releasing hormone (GHRH), the signal that tells the pituitary to release growth hormone. The original version carries a "drug affinity complex" (DAC) that binds albumin and extends its half-life to days. Products sold as "CJC-1295 without DAC" are a different, shorter-acting molecule usually called modified GRF(1-29).
CJC-1295 is not an FDA-approved drug. Growth-hormone-releasing factors and their analogs are prohibited in sport under WADA rules.
Status reflects public FDA actions and reporting as of October 8, 2026. An advisory committee vote is a recommendation, not an FDA decision, and inclusion on a compounding list is not FDA approval.
A 2006 study in healthy adults (Teichman et al., Journal of Clinical Endocrinology & Metabolism) found that single injections raised growth hormone and IGF-1 levels for days. Raising a hormone level is not the same as improving health outcomes, and development for clinical use did not continue.
nnng.com does not publish doses, cycles or protocols for peptides. For approved drugs, the dose comes from the FDA-approved prescribing information and your prescriber. For unapproved compounds there is no established human dose, and numbers that circulate online are usually extrapolated from animal studies or written by sellers. If a clinician has already prescribed a dose, our reconstitution calculator converts that prescribed amount into syringe units. It is arithmetic only and does not suggest a dose.